BioStem Adds Seasoned Auditor to Board Amid Expansion Plans
Event summary
- BioStem Technologies appointed Jodi Ungrodt to its Board of Directors, effective March 18, 2026.
- Ungrodt will also serve as Chair of the Audit Committee, replacing Brandon Poe who became CFO in August 2025.
- Ungrodt brings nearly three decades of experience advising life sciences companies at Ernst & Young, including advising on over 30 IPOs.
- BioStem plans to expand its business beyond chronic wound care and increase its visibility in public markets in 2026.
- Brandon Poe, former board member, transitioned to the role of Chief Financial Officer.
The big picture
The appointment of Jodi Ungrodt signals BioStem's intent to strengthen its governance and financial controls as it pursues expansion and increased public market presence. This move is typical of smaller, publicly traded MedTech companies seeking to bolster investor confidence and prepare for potential capital raises. The timing aligns with a broader trend of increased regulatory focus and investor demand for robust financial oversight within the regenerative medicine sector.
What we're watching
- Governance Dynamics
- The Audit Committee's oversight of BioStem's financial reporting will be critical given the company's stated plans for increased public market visibility and expansion, requiring heightened scrutiny.
- Regulatory Headwinds
- BioStem's adherence to cGTP and cGMP standards, already overseen by the AATB, will face increased pressure as the company expands into acute applications and potentially seeks broader regulatory approvals.
- Execution Risk
- The success of BioStem’s expansion beyond chronic wound care will depend on its ability to effectively leverage its proprietary technologies and navigate the competitive landscape in new therapeutic areas.
Related topics